Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Prostate Cancer

Free Subscription Articles published in Proc Natl Acad Sci U S A Retrieve available abstracts of 28 articles: HTML format

Single Articles

October 2024
1. WANG Z, Yu H, Bao W, Qu M, et al
   Proteomic and phosphoproteomic landscape of localized prostate cancer unveils distinct molecular subtypes and insights into precision therapeutics.
   Proc Natl Acad Sci U S A. 2024;121:e2402741121.
   PubMed     Abstract available
   
   
   September 2024
2. SU XA, Stopsack KH, Schmidt DR, Ma D, et al
   RAD21 promotes oncogenesis and lethal progression of prostate cancer.
   Proc Natl Acad Sci U S A. 2024;121:e2405543121.
   PubMed     Abstract available
   
   
   August 2024
3. YU G, Corn PG, Mak CSL, Liang X, et al
   Prostate cancer-induced endothelial-cell-to-osteoblast transition drives immunosuppression in the bone-tumor microenvironment through Wnt pathway-induced M2 macrophage polarization.
   Proc Natl Acad Sci U S A. 2024;121:e2402903121.
   PubMed     Abstract available
   
   
   July 2024
4. PORNOUR M, Jeon HY, Ryu H, Khadka S, et al
   USP11 promotes prostate cancer progression by up-regulating AR and c-Myc activity.
   Proc Natl Acad Sci U S A. 2024;121:e2403331121.
   PubMed     Abstract available
   
   
   
5. ZAIDI S, Park J, Chan JM, Roudier MP, et al
   Single-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen-targeted therapies.
   Proc Natl Acad Sci U S A. 2024;121:e2322203121.
   PubMed     Abstract available
   
   
   April 2024
6. HE T, Cheng C, Qiao Y, Cho H, et al
   Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer.
   Proc Natl Acad Sci U S A. 2024;121:e2322563121.
   PubMed     Abstract available
   
   
   December 2023
7. SUSHENTSEV N, Hamm G, Richings J, McLean MA, et al
   Imaging tumor lactate is feasible for identifying intermediate-risk prostate cancer patients with postsurgical biochemical recurrence.
   Proc Natl Acad Sci U S A. 2023;120:e2312261120.
   PubMed     Abstract available
   
   
   November 2023
8. MAJI S, Pradhan AK, Kumar A, Bhoopathi P, et al
   MDA-9/Syntenin in the tumor and microenvironment defines prostate cancer bone metastasis.
   Proc Natl Acad Sci U S A. 2023;120:e2307094120.
   PubMed     Abstract available
   
   
   August 2023
9. WANG Z, Petricca J, Liu M, Zhang S, et al
   SETD7 functions as a transcription repressor in prostate cancer via methylating FOXA1.
   Proc Natl Acad Sci U S A. 2023;120:e2220472120.
   PubMed     Abstract available
   
   
   July 2023
10. QIAO Y, Wotring JW, Zheng Y, Zhang CJ, et al
    Proxalutamide reduces SARS-CoV-2 infection and associated inflammatory response.
    Proc Natl Acad Sci U S A. 2023;120:e2221809120.
    PubMed     Abstract available
    
    
    
11. CHEN X, Yang HT, Zhang B, Phillips JW, et al
    The RNA-binding proteins hnRNP H and F regulate splicing of a MYC-dependent HRAS exon in prostate cancer cells.
    Proc Natl Acad Sci U S A. 2023;120:e2220190120.
    PubMed     Abstract available
    
    
    May 2023
12. SINGH R, Meng H, Shen T, Lumahan LEV, et al
    TRAF4-mediated nonproteolytic ubiquitination of androgen receptor promotes castration-resistant prostate cancer.
    Proc Natl Acad Sci U S A. 2023;120:e2218229120.
    PubMed     Abstract available
    
    
    April 2023
13. ZHANG W, Lee AM, Jena S, Huang Y, et al
    Computational drug discovery for castration-resistant prostate cancers through in vitro drug response modeling.
    Proc Natl Acad Sci U S A. 2023;120:e2218522120.
    PubMed     Abstract available
    
    
    January 2023
14. THIYAGARAJAN T, Ponnusamy S, Hwang DJ, He Y, et al
    Inhibiting androgen receptor splice variants with cysteine-selective irreversible covalent inhibitors to treat prostate cancer.
    Proc Natl Acad Sci U S A. 2023;120:e2211832120.
    PubMed     Abstract available
    
    
    October 2022
15. SHEN T, Dong B, Meng Y, Moore DD, et al
    A COP1-GATA2 axis suppresses AR signaling and prostate cancer.
    Proc Natl Acad Sci U S A. 2022;119:e2205350119.
    PubMed     Abstract available
    
    
    September 2022
16. SUN R, Wei T, Ding D, Zhang J, et al
    CYCLIN K down-regulation induces androgen receptor gene intronic polyadenylation, variant expression and PARP inhibitor vulnerability in castration-resistant prostate cancer.
    Proc Natl Acad Sci U S A. 2022;119:e2205509119.
    PubMed     Abstract available
    
    
    July 2022
17. KORSEN JA, Gutierrez JA, Tully KM, Carter LM, et al
    Delta-like ligand 3-targeted radioimmunotherapy for neuroendocrine prostate cancer.
    Proc Natl Acad Sci U S A. 2022;119:e2203820119.
    PubMed     Abstract available
    
    
    June 2022
18. LEE J, Olivieri C, Ong C, Masterson LR, et al
    Raf Kinase Inhibitory Protein regulates the cAMP-dependent protein kinase signaling pathway through a positive feedback loop.
    Proc Natl Acad Sci U S A. 2022;119:e2121867119.
    PubMed     Abstract available
    
    
    May 2022
19. BARATCHIAN M, Tiwari R, Khalighi S, Chakravarthy A, et al
    H3K9 methylation drives resistance to androgen receptor-antagonist therapy in prostate cancer.
    Proc Natl Acad Sci U S A. 2022;119:e2114324119.
    PubMed     Abstract available
    
    
    April 2022
20. VAN HEIJSTER FHA, Breukels V, Jansen KCFJ, Schalken JA, et al
    Carbon sources and pathways for citrate secreted by human prostate cancer cells determined by NMR tracing and metabolic modeling.
    Proc Natl Acad Sci U S A. 2022;119:e2024357119.
    PubMed     Abstract available
    
    
    January 2022
21. BAKHT MK, Hayward JJ, Shahbazi-Raz F, Skubal M, et al
    Identification of alternative protein targets of glutamate-ureido-lysine associated with PSMA tracer uptake in prostate cancer cells.
    Proc Natl Acad Sci U S A. 2022;119.
    PubMed     Abstract available
    
    
    
22. LIAO Y, Chen CH, Xiao T, de la Pena Avalos B, et al
    Inhibition of EZH2 transactivation function sensitizes solid tumors to genotoxic stress.
    Proc Natl Acad Sci U S A. 2022;119.
    PubMed     Abstract available
    
    
    October 2021
23. BELLO T, Paindelli C, Diaz-Gomez LA, Melchiorri A, et al
    Computational modeling identifies multitargeted kinase inhibitors as effective therapies for metastatic, castration-resistant prostate cancer.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available
    
    
    September 2021
24. YOSHIHAMA Y, LaBella KA, Kim E, Bertolet L, et al
    AR-negative prostate cancer is vulnerable to loss of JMJD1C demethylase.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available
    
    
    August 2021
25. 
    Correction for Baek et al., Ligand-specific allosteric regulation of coactivator functions of androgen receptor in prostate cancer cells.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed    
    
    
    
26. SHRESTHA E, Coulter JB, Guzman W, Ozbek B, et al
    Oncogenic gene fusions in nonneoplastic precursors as evidence that bacterial infection can initiate prostate cancer.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available
    
    
    
27. FENG W, Cao Z, Lim PX, Zhao H, et al
    Rapid interrogation of cancer cell of origin through CRISPR editing.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available
    
    
    March 2021
28. WU WF, Wang L, Spetsieris N, Boukovala M, et al
    Estrogen receptor beta and treatment with a phytoestrogen are associated with inhibition of nuclear translocation of EGFR in the prostate.
    Proc Natl Acad Sci U S A. 2021;118:e2011269118.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.